These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
182 related articles for article (PubMed ID: 24808020)
21. Multigene panel next generation sequencing in a patient with cherry red macular spot: Identification of two novel mutations in Mütze U; Bürger F; Hoffmann J; Tegetmeyer H; Heichel J; Nickel P; Lemke JR; Syrbe S; Beblo S Mol Genet Metab Rep; 2017 Mar; 10():1-4. PubMed ID: 27942463 [TBL] [Abstract][Full Text] [Related]
22. Type II sialidosis: review of the clinical spectrum and identification of a new splicing defect with chitotriosidase assessment in two patients. Caciotti A; Di Rocco M; Filocamo M; Grossi S; Traverso F; d'Azzo A; Cavicchi C; Messeri A; Guerrini R; Zammarchi E; Donati MA; Morrone A J Neurol; 2009 Nov; 256(11):1911-5. PubMed ID: 19568825 [TBL] [Abstract][Full Text] [Related]
23. Mutation of the CLN6 gene in teenage-onset progressive myoclonus epilepsy. Andrade DM; Paton T; Turnbull J; Marshall CR; Scherer SW; Minassian BA Pediatr Neurol; 2012 Sep; 47(3):205-8. PubMed ID: 22883287 [TBL] [Abstract][Full Text] [Related]
24. Characterization of severe action myoclonus in sialidoses. Canafoglia L; Franceschetti S; Uziel G; Ciano C; Scaioli V; Guerrini R; Visani E; Panzica F Epilepsy Res; 2011 Mar; 94(1-2):86-93. PubMed ID: 21330109 [TBL] [Abstract][Full Text] [Related]
25. Five novel mutations in the lysosomal sialidase gene (NEU1) in type II sialidosis patients and assessment of their impact on enzyme activity and intracellular targeting using adenovirus-mediated expression. Pattison S; Pankarican M; Rupar CA; Graham FL; Igdoura SA Hum Mutat; 2004 Jan; 23(1):32-9. PubMed ID: 14695530 [TBL] [Abstract][Full Text] [Related]
26. Mucolipidosis I, the cherry red-spot--myoclonus syndrome and neuraminidase deficiency. Spranger J; Cantz M Birth Defects Orig Artic Ser; 1978; 14(6B):105-12. PubMed ID: 728556 [No Abstract] [Full Text] [Related]
27. Genetic and clinical characterization of mainland Chinese patients with sialidosis type 1. Han X; Wu S; Wang M; Li H; Huang Y; Sui R Mol Genet Genomic Med; 2020 Aug; 8(8):e1316. PubMed ID: 32453490 [TBL] [Abstract][Full Text] [Related]
28. Neuraminidase activities in sialidosis and mucolipidosis. Kuriyama M; Miyatake T; Owada M; Kitagawa T J Neurol Sci; 1982 May; 54(2):181-7. PubMed ID: 7097297 [TBL] [Abstract][Full Text] [Related]
29. Child Neurology: Type 1 sialidosis due to a novel mutation in Aravindhan A; Veerapandiyan A; Earley C; Thulasi V; Kresge C; Kornitzer J Neurology; 2018 Mar; 90(13):622-624. PubMed ID: 29581327 [No Abstract] [Full Text] [Related]
30. [Two siblings with adult-onset sialidosis type I (cherry-red spot-myoclonus syndrome)]. Tana T; Komine Y; Kanzato N; Kawazoe N; Fukiyama K Rinsho Shinkeigaku; 1995 Jul; 35(7):803-5. PubMed ID: 8777807 [TBL] [Abstract][Full Text] [Related]
31. [A new observation of cherry-red spot myoclonus syndrome (author's transl)]. Martin JJ Acta Neurol Belg; 1980; 80(1):30-6. PubMed ID: 7361541 [TBL] [Abstract][Full Text] [Related]
32. Pitfalls in Diagnosing Neuraminidase Deficiency: Psychosomatics and Normal Sialic Acid Excretion. Schene IF; Kalinina Ayuso V; de Sain-van der Velden M; van Gassen KL; Cuppen I; van Hasselt PM; Visser G JIMD Rep; 2016; 25():9-13. PubMed ID: 26141460 [TBL] [Abstract][Full Text] [Related]
33. Modeling Sialidosis with Neural Precursor Cells Derived from Patient-Derived Induced Pluripotent Stem Cells. Seol B; Kim YD; Cho YS Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33922276 [TBL] [Abstract][Full Text] [Related]
34. Sialidosis type 1: cherry red spot-myoclonus syndrome with sialidase deficiency and altered electrophoretic mobility of some enzymes known to be glycoproteins. II. Enzymes studies. Swallow DM; Evans L; Stewart G; Thomas PK; Abrams JD Ann Hum Genet; 1979 Jul; 43(1):27-35. PubMed ID: 496393 [TBL] [Abstract][Full Text] [Related]
35. Infantile sialidosis: natural history in a preterm infant with two new pathogenic mutations and new ocular findings. Pérez-Cabeza MI; Borrás F; Moreno-Medinilla EE; Bardán-Rebollar D; Ferrer-López I; Rodríguez-García E; Jiménez-Machado R; Castro-Vega I; Benito C; Escudero J; Yahyaoui R J AAPOS; 2019 Apr; 23(2):102-104. PubMed ID: 30445145 [TBL] [Abstract][Full Text] [Related]
36. Gene therapy corrects the neurological deficits of mice with sialidosis. Hwu WL; Chang K; Liu YH; Wang HC; Lee NC; Chien YH Gene Ther; 2024 May; 31(5-6):263-272. PubMed ID: 38321198 [TBL] [Abstract][Full Text] [Related]
37. Clinical and Structural Characteristics of NEU1 Variants Causing Sialidosis Type 1. Li Y; Liu Y; Wang R; Ao R; Xiang F; Zhang X; Wang X; Yu S J Mov Disord; 2024 Jul; 17(3):282-293. PubMed ID: 38600684 [TBL] [Abstract][Full Text] [Related]
38. NEU1 mutation in a Korean infant with type 2 sialidosis presenting as isolated fetal ascites. Lee YJ; Son SK; Park JH; Song JS; Cheon CK Pediatr Neonatol; 2015 Feb; 56(1):68-9. PubMed ID: 25223955 [No Abstract] [Full Text] [Related]
39. Identification of a CTL4/Neu1 fusion transcript in a sialidosis patient. Uhl J; Penzel R; Sergi C; Kopitz J; Otto HF; Cantz M FEBS Lett; 2002 Jun; 521(1-3):19-23. PubMed ID: 12067718 [TBL] [Abstract][Full Text] [Related]
40. Cloning, expression and chromosomal mapping of human lysosomal sialidase and characterization of mutations in sialidosis. Pshezhetsky AV; Richard C; Michaud L; Igdoura S; Wang S; Elsliger MA; Qu J; Leclerc D; Gravel R; Dallaire L; Potier M Nat Genet; 1997 Mar; 15(3):316-20. PubMed ID: 9054950 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]